CYP3A4 inhibitor
- Inhibits CYP3A4
- CYP3A4 substrate exposure can rise
- Effect is greatest for sensitive substrates
- Toxicity risk rises with narrow-index victims
- Inhibition often begins faster than induction
- Largest DDI burden; gut + liver both contribute.
Interaction at a glance
Magnitude / time course
- Inhibits CYP3A4
- CYP3A4 substrate exposure can rise
Mechanism
- Effect is greatest for sensitive substrates
- Inhibition often begins faster than induction
- Largest DDI burden; gut + liver both contribute.
Clinical consequence
- Toxicity risk rises with narrow-index victims
Self-check
- What is the main clinical risk of CYP3A4 inhibitor?
Toxicity risk rises with narrow-index victims.
- Which enzyme or transporter is central to the CYP3A4 inhibitor interaction?
CYP3A4.
Drugs in this interaction (19)
All interaction examples · Open the interactive console ↗